What is the projected market valuation of the Brain Tumor Diagnostics Market by 2035?

The Brain Tumor Diagnostics Market is projected to reach approximately 5.264 USD Billion by 2035. Read More

What was the market valuation of the Brain Tumor Diagnostics Market in 2024?

In 2024, the market valuation of the Brain Tumor Diagnostics Market was 2.49 USD Billion. Read More

What is the expected CAGR for the Brain Tumor Diagnostics Market during the forecast period 2025 - 2035?

The expected CAGR for the Brain Tumor Diagnostics Market during the forecast period 2025 - 2035 is 7.04%. Read More

Which companies are considered key players in the Brain Tumor Diagnostics Market?

Key players in the Brain Tumor Diagnostics Market include Siemens Healthineers, GE Healthcare, and Philips Healthcare, among others. Read More

What are the main modalities contributing to the Brain Tumor Diagnostics Market?

The main modalities include Neuroimaging, Biopsy, Laboratory Tests, and Genetic Testing, with Neuroimaging valued at 1.99 USD Billion by 2035. Read More

How does the market for genetic testing in brain tumor diagnostics appear to be evolving?

The market for genetic testing is projected to grow from 0.25 USD Billion in 2024 to 0.5 USD Billion by 2035. Read More

What imaging techniques are primarily utilized in brain tumor diagnostics?

The primary imaging techniques include Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET), with MRI expected to reach 1.99 USD Billion by 2035. Read More

What sample types are commonly used in brain tumor diagnostics?

Common sample types include Tissue Biopsy, Blood, and Cerebrospinal Fluid (CSF), with Tissue Biopsy projected to reach 1.99 USD Billion by 2035. Read More

How does the market for biomarkers in brain tumor diagnostics appear to be developing?

The market for biomarkers, including IDH1 and ATRX, is expected to grow significantly, with IDH1 projected to reach 0.999 USD Billion by 2035. Read More

Brain Tumor Diagnostics Market

Q: What diagnostic purposes are driving the Brain Tumor Diagnostics Market?

Key diagnostic purposes include Pre-Operative Diagnosis, Post-Operative Monitoring, Treatment Selection, and Prognosis Prediction. Read More

ID: MRFR/LS/7588-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Brain Tumor Diagnostics Market Research Report By Modality (Neuroimaging, Biopsy, Laboratory Tests, Genetic Testing), By Biomarker (IDH1, ATRX, BRAF, EGFR, MGMT), By Diagnostic Purpose (Pre-Operative Diagnosis, Post-Operative Monitoring, Treatment Selection, Prognosis Prediction), By Imaging Technique (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT)), By Sample Type (Tissue Biopsy, Blood, Cerebrospinal Fluid (CSF)) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa- Growth & Industry Forecast 2025 To 2035

Brain Tumor Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Modality (USD Billion)
  1. 4.1.1 Neuroimaging
  2. 4.1.2 Biopsy
  3. 4.1.3 Laboratory Tests
  4. 4.1.4 Genetic Testing
2. 4.2 Healthcare, BY Biomarker (USD Billion)
  1. 4.2.1 IDH1
  2. 4.2.2 ATRX
  3. 4.2.3 BRAF
  4. 4.2.4 EGFR
  5. 4.2.5 MGMT
3. 4.3 Healthcare, BY Diagnostic Purpose (USD Billion)
  1. 4.3.1 Pre-Operative Diagnosis
  2. 4.3.2 Post-Operative Monitoring
  3. 4.3.3 Treatment Selection
  4. 4.3.4 Prognosis Prediction
4. 4.4 Healthcare, BY Imaging Technique (USD Billion)
  1. 4.4.1 Magnetic Resonance Imaging (MRI)
  2. 4.4.2 Computed Tomography (CT)
  3. 4.4.3 Positron Emission Tomography (PET)
  4. 4.4.4 Single Photon Emission Computed Tomography (SPECT)
5. 4.5 Healthcare, BY Sample Type (USD Billion)
  1. 4.5.1 Tissue Biopsy
  2. 4.5.2 Blood
  3. 4.5.3 Cerebrospinal Fluid (CSF)
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Siemens Healthineers (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GE Healthcare (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Philips Healthcare (NL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche Diagnostics (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Abbott Laboratories (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bayer AG (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Fujifilm Holdings Corporation (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Canon Medical Systems (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hitachi Medical Corporation (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY MODALITY
4. 6.4 US MARKET ANALYSIS BY BIOMARKER
5. 6.5 US MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6. 6.6 US MARKET ANALYSIS BY IMAGING TECHNIQUE
7. 6.7 US MARKET ANALYSIS BY SAMPLE TYPE
8. 6.8 CANADA MARKET ANALYSIS BY MODALITY
9. 6.9 CANADA MARKET ANALYSIS BY BIOMARKER
10. 6.10 CANADA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
11. 6.11 CANADA MARKET ANALYSIS BY IMAGING TECHNIQUE
12. 6.12 CANADA MARKET ANALYSIS BY SAMPLE TYPE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY MODALITY
15. 6.15 GERMANY MARKET ANALYSIS BY BIOMARKER
16. 6.16 GERMANY MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
17. 6.17 GERMANY MARKET ANALYSIS BY IMAGING TECHNIQUE
18. 6.18 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
19. 6.19 UK MARKET ANALYSIS BY MODALITY
20. 6.20 UK MARKET ANALYSIS BY BIOMARKER
21. 6.21 UK MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
22. 6.22 UK MARKET ANALYSIS BY IMAGING TECHNIQUE
23. 6.23 UK MARKET ANALYSIS BY SAMPLE TYPE
24. 6.24 FRANCE MARKET ANALYSIS BY MODALITY
25. 6.25 FRANCE MARKET ANALYSIS BY BIOMARKER
26. 6.26 FRANCE MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
27. 6.27 FRANCE MARKET ANALYSIS BY IMAGING TECHNIQUE
28. 6.28 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
29. 6.29 RUSSIA MARKET ANALYSIS BY MODALITY
30. 6.30 RUSSIA MARKET ANALYSIS BY BIOMARKER
31. 6.31 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
32. 6.32 RUSSIA MARKET ANALYSIS BY IMAGING TECHNIQUE
33. 6.33 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
34. 6.34 ITALY MARKET ANALYSIS BY MODALITY
35. 6.35 ITALY MARKET ANALYSIS BY BIOMARKER
36. 6.36 ITALY MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
37. 6.37 ITALY MARKET ANALYSIS BY IMAGING TECHNIQUE
38. 6.38 ITALY MARKET ANALYSIS BY SAMPLE TYPE
39. 6.39 SPAIN MARKET ANALYSIS BY MODALITY
40. 6.40 SPAIN MARKET ANALYSIS BY BIOMARKER
41. 6.41 SPAIN MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
42. 6.42 SPAIN MARKET ANALYSIS BY IMAGING TECHNIQUE
43. 6.43 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY MODALITY
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY IMAGING TECHNIQUE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY MODALITY
51. 6.51 CHINA MARKET ANALYSIS BY BIOMARKER
52. 6.52 CHINA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
53. 6.53 CHINA MARKET ANALYSIS BY IMAGING TECHNIQUE
54. 6.54 CHINA MARKET ANALYSIS BY SAMPLE TYPE
55. 6.55 INDIA MARKET ANALYSIS BY MODALITY
56. 6.56 INDIA MARKET ANALYSIS BY BIOMARKER
57. 6.57 INDIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
58. 6.58 INDIA MARKET ANALYSIS BY IMAGING TECHNIQUE
59. 6.59 INDIA MARKET ANALYSIS BY SAMPLE TYPE
60. 6.60 JAPAN MARKET ANALYSIS BY MODALITY
61. 6.61 JAPAN MARKET ANALYSIS BY BIOMARKER
62. 6.62 JAPAN MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
63. 6.63 JAPAN MARKET ANALYSIS BY IMAGING TECHNIQUE
64. 6.64 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY MODALITY
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY IMAGING TECHNIQUE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
70. 6.70 MALAYSIA MARKET ANALYSIS BY MODALITY
71. 6.71 MALAYSIA MARKET ANALYSIS BY BIOMARKER
72. 6.72 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
73. 6.73 MALAYSIA MARKET ANALYSIS BY IMAGING TECHNIQUE
74. 6.74 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
75. 6.75 THAILAND MARKET ANALYSIS BY MODALITY
76. 6.76 THAILAND MARKET ANALYSIS BY BIOMARKER
77. 6.77 THAILAND MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
78. 6.78 THAILAND MARKET ANALYSIS BY IMAGING TECHNIQUE
79. 6.79 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
80. 6.80 INDONESIA MARKET ANALYSIS BY MODALITY
81. 6.81 INDONESIA MARKET ANALYSIS BY BIOMARKER
82. 6.82 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
83. 6.83 INDONESIA MARKET ANALYSIS BY IMAGING TECHNIQUE
84. 6.84 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
85. 6.85 REST OF APAC MARKET ANALYSIS BY MODALITY
86. 6.86 REST OF APAC MARKET ANALYSIS BY BIOMARKER
87. 6.87 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
88. 6.88 REST OF APAC MARKET ANALYSIS BY IMAGING TECHNIQUE
89. 6.89 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY MODALITY
92. 6.92 BRAZIL MARKET ANALYSIS BY BIOMARKER
93. 6.93 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
94. 6.94 BRAZIL MARKET ANALYSIS BY IMAGING TECHNIQUE
95. 6.95 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
96. 6.96 MEXICO MARKET ANALYSIS BY MODALITY
97. 6.97 MEXICO MARKET ANALYSIS BY BIOMARKER
98. 6.98 MEXICO MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
99. 6.99 MEXICO MARKET ANALYSIS BY IMAGING TECHNIQUE
100. 6.100 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
101. 6.101 ARGENTINA MARKET ANALYSIS BY MODALITY
102. 6.102 ARGENTINA MARKET ANALYSIS BY BIOMARKER
103. 6.103 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
104. 6.104 ARGENTINA MARKET ANALYSIS BY IMAGING TECHNIQUE
105. 6.105 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODALITY
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMAGING TECHNIQUE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY MODALITY
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY IMAGING TECHNIQUE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY MODALITY
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY IMAGING TECHNIQUE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
122. 6.122 REST OF MEA MARKET ANALYSIS BY MODALITY
123. 6.123 REST OF MEA MARKET ANALYSIS BY BIOMARKER
124. 6.124 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
125. 6.125 REST OF MEA MARKET ANALYSIS BY IMAGING TECHNIQUE
126. 6.126 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY MODALITY, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY MODALITY, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY BIOMARKER, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY BIOMARKER, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY DIAGNOSTIC PURPOSE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DIAGNOSTIC PURPOSE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY IMAGING TECHNIQUE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY IMAGING TECHNIQUE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.2.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.2.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.2.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.2.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.3.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.3.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.3.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.3.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.4.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.4.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.4.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.4.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.5.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.5.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.5.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.5.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.6.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.6.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.6.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.6.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.7.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.7.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.7.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.7.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.8.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.8.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.8.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.8.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.9.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.9.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.9.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.9.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.10.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.10.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.10.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.10.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.11.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.11.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.11.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.11.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.12.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.12.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.12.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.12.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.13.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.13.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.13.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.13.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.14.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.14.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.14.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.14.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.15.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.15.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.15.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.15.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.16.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.16.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.16.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.16.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.17.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.17.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.17.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.17.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.18.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.18.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.18.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.18.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.19.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.19.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.19.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.19.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.20.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.20.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.20.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.20.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.21.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.21.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.21.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.21.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.22.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.22.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.22.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.22.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.23.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.23.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.23.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.23.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.24.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.24.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.24.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.24.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.25.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.25.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.25.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.25.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.26.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.26.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.26.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.26.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.27.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.27.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.27.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.27.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.28.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.28.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.28.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.28.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.29.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.29.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.29.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.29.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY MODALITY, 2025-2035 (USD Billion)
  2. 7.30.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.30.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
  4. 7.30.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
  5. 7.30.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Modality (USD Billion, 2025-2035)

Neuroimaging
Biopsy
Laboratory Tests
Genetic Testing

Healthcare By Biomarker (USD Billion, 2025-2035)

IDH1
ATRX
BRAF
EGFR
MGMT

Healthcare By Diagnostic Purpose (USD Billion, 2025-2035)

Pre-Operative Diagnosis
Post-Operative Monitoring
Treatment Selection
Prognosis Prediction

Healthcare By Imaging Technique (USD Billion, 2025-2035)

Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)

Healthcare By Sample Type (USD Billion, 2025-2035)

Tissue Biopsy
Blood
Cerebrospinal Fluid (CSF)

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”